The invention relates generally to a biopsy tissue markers. More specifically, the invention further relates to a biocompatible tissue site marker that is visible under various modes of imaging.
Advances in modern medical imaging technologies such as X-ray, ultrasound, or magnetic resonance imaging make it possible to identify and to biopsy tumors while they are still small. When dealing with a small tumor, especially after a portion of the tumor has been removed for biopsy, it is sometimes difficult to locate the tumor at a later time for treatment. This is particularly true in the case of tumors in the breast, where the ability to visualize a small growth may depend upon the manner in which the breast is positioned or compressed during the procedure. In addition, prior to surgically removing a tumor, it is often advantageous to try to shrink the tumor by chemotherapy or irradiation. This is especially true in the case of breast cancer, where conservation of breast tissue is a concern. Shrinkage of the tumor can sometimes make it difficult for the surgeon to locate the tumor.
A solution to this problem is to place a marker within the target tissues at the time of biopsy which can be visualized under a variety of imaging modalities to facilitate finding the tumor at a later time. When a suspicious mass is detected, a sample is taken by biopsy, often, but not necessarily, using a specialized instrument such as a biopsy needle. The needle is inserted in the breast while the position of the needle is monitored using fluoroscopy, ultrasonic imaging, X-rays, MRI or other suitable imaging modalities.
In a new procedure, called stereotactic needle biopsy, the breast is compressed between the plates of a mammography apparatus and two separate X-rays are taken from different points of reference. The exact position of the mass or lesion is calculated within the breast. The coordinates of the lesion are then programmed into a mechanical stereotactic apparatus which guides the biopsy needle to the lesion.
Irrespective of the biopsy technique, the surgical site may need to be examined or accessed for surgical treatment of a cancerous lesion. Treatment requires the surgeon or radiologist locate the lesion precisely and this may need to be done repeatedly over a period of time. Since treatment may alter the host tissue, the function of a marker even more important.
U.S. Pat. No. 6,725,083 for “Tissue site markers for in vivo imaging” describes biopsy site markers and methods that permit conventional imaging techniques to be used, such as ultrasonic imaging. The biopsy site markers have high ultrasound reflectivity due to high contrast of acoustic impedance resulting from gas-filled internal pores. The markers may have a non-uniform surface. The patent discloses the use of materials such as metal, ceramic materials, metal oxides, polymer, and composites and mixtures thereof.
U.S. Pat. No. 6,350,244 for “Bioabsorable markers for use in biopsy procedure” discloses a breast tissue marker that allows the marker to be left in place avoiding the need for surgical removal. One type of marker takes the form of hollow spheres made of polylactite acid filled with iodine or other radiopaque material to make them visible under X-rays and/or ultrasound. The radiopaque materials are also bioabsorbable. Another type of marker disclosed is a solid marker of pre-mixed radiopaque material and a bioabsorbable material. The solid markers may also include dyes and radioactive materials.
U.S. Pat. No. 6,347,241 for “Ultrasonic and x-ray detectable biopsy site marker and apparatus for applying it” shows a biopsy site marker of small bodies or pellets of gelatin which enclose substantially a radioopaque object. The pellets are deposited at the biopsy site by an applicator device inserted in the biopsy site. Several gelatin pellets are deposited through the tube. The radio opaque core in the gelatin bodies are of a non-biological material and structure which are readily identified during X-ray observations.
U.S. Pat. No. 6,161,034 for “Methods and chemical preparations for time-limited marking of biopsy sites” describes markers that remain present to permit detection and location of the biopsy site. The markers are later absorbed by the host. The patent discloses gelatin, collagen, balloons and detectability provided by AgCl; Agl; BaCO3; BaSO4; K; CaCO3; ZnO; Al2 O3; and combinations of these.
US Patent Publication No. 2006/0079805 for “Site marker visible under multiple modalities” describes site markers that include balls or particles which are bonded together to form a marker body. The balls or particles are made from biocompatible materials such as titanium, stainless steel or platinum. The balls or particles are described as being bonded together by sintering or by adhesive such as epoxy. An alternative embodiment has at least one continuous strand of wire of biocompatible material such as titanium, stainless steel, platinum, or other suitable material, compressed to form a mass that resembles a ball of yarn. Another alternative is a resonating capsule, or a rod with drilled holes.
US Patent Publication No. 2006/0036165 for “Tissue site markers for in vivo imaging” shows ultrasound-detectable markers whose shapes are distinct in an image from biological shapes. Various shapes are disclosed including cylinders, coils, and other more complex shapes.
It is believed that most known tissue markers have a disadvantage in that they are not visible under all available imaging modalities. The features of a marker that make it stand out under X-rays do not necessarily make them stand out under MRI or ultrasound imaging. One prior art mechanism for addressing the need for multiple-imaging-mode markers is to employ a combination of metal structure and biodegradable foam to provide ultrasonic imaging visibility, MRI visibility and x-ray visibility. In this case, the metal structure provides x-ray visibility and biodegradable foam provides visibility in ultrasonic imaging.
There is a need for site markers made from biocompatible materials that are visible under various modes of imaging to reduce the number of procedures that patients must undergo in detection and treatment of cancer or any disease requiring the user of tissue markers. It will be a valuable contribution to the art for a marker with a simple design and superior biocompatibility can be provided. Also, selectable bioabsorability by the host may be an advantage as well.
A hydroxyapatite or porous metal or non-metal-based biopsy marker is visible in multiple imaging modalities. In a preferred embodiment, hydroxyapatite, a component of natural bone, is used. This material is highly visible when viewed using X-ray imaging. The ultrasonic visibility may be provided by creating one or more voids within the hydroxyapatite marker and entrapping a biocompatible gas within the void or voids. The biocompatible gas provides a low density structure within the marker body which provides high contrast when viewed using ultrasonic imaging equipment. Also, hydroxyapatite has the advantage of being very biocompatible. In addition, if biodegradability is desired, hydroxyl apatite is capable of being rendered in a form that makes it long-lasting, but ultimately biodegradable as well.
The manufacture of porous hydroxyapatite performs or molded forms is well known. The hydroxyapatite can be made porous by many methods known in ceramic manufacturing art. These methods include but not limited to: molding the hydroxyapatite particles to a desired geometry and then sintering the green mass. The preferred porosity levels in porous Hydroxyapatite could range from 30% to 80%, and more preferably, from 60 to 80%. One exemplary method is to mix powdered hydroxyapatite with a removable material to form a slurry which when hardened can be removed and then to sinter the hydroxyapatite to form a porous structure. Examples of removable material include various soluble polymers, naphthalene, and others. Purified hydroxyapatite powder can be made from known processes or obtained from natural sources such as coral.
In an embodiment, a porous hydroxyapatite article may be obtained, for example from commercial sources such as Berkeley Advanced Biomaterials, Inc and incubated in carbon dioxide atmosphere to fill the pores. The disk is visible under X-ray and ultrasonic imaging.
Material other than hydroxyapatite can be used to make a marker visible under multiple imaging modalities. For example, a biocompatible porous ceramic may be used alone or in combination with a biocompatible impermeable jacket, such as a coating of PTFE. The porous ceramic material can be produced by sintering particles with a sufficient void fraction to make the resulting article distinct under ultrasound. Ceramics containing mixtures of materials may be employed to enhance radio-opacity. For example, ceramics can contain metallic inclusions. Ceramic particles (or metal-ceramic particle mixtures) having a packing density of a desired fraction, for example 70%, may be sintered to create a mass. The result may have no, or limited, connections between the void spaces so that the result needs no impermeable jacket to avoid the voids filling with fluids. Alternatively, a coating may be provided to prevent ingress of fluids. The coating need not be mechanically continuous over the article if it is sufficient to retard ingress of moisture. For example, the coating material may be hydrophobic. In a variation, techniques used for making refractory foams may be employed to create a marker.
In another embodiment, a biocompatible porous metal is used in place of hydroxyapatite. The porous metal can be produced by mechanical methods known in the art such as sand blasting. Other methods such as laser etching, chemical etching or powder metallurgical methods including sintering could also be used. In one preferred approach, porous metals are obtained by compacting a metal powder to a desired shape in presence of a polymeric and non-polymeric binder and then sintering the metal powder particles to form a homogenous metal mass with predetermined porosity/density. Many metals and alloys suitable for long term implant could be used and these include but not limited to: Nitinol, gold, silver, stainless steel, cobalt-chromium alloy, titanium, tantalum, and tungsten or combination thereof.
The shape and geometry of the porous biopsy marker can depend on the clinical application. In general cylindrical, spherical, disk like shapes are preferred. Irregular shapes may also be used.
According to an embodiment, an intracorporeal marker marks a site within living tissue of a host. The marker has a body of porous hydroxyapatite whose size and shape permit visualization under ultrasonic and radiation imaging modalities. Preferably, the shape is generally cylindrical. In one embodiment, the marker has a lower density core region and a higher density surface region.
According to an embodiment, an intracorporeal marker marks a site within living tissue of a host. The marker has an ultrasound-detectable portion defined by boundaries that are distinctly different from normal tissue features. The ultrasound-detectable portion is of a material that exhibits high contrast in acoustical impedance compared to the host tissue. The same portion, or a different portion, of a material exhibits high contrast in at least one type of radiation imaging. The portion or the same or different portion includes at least one of porous ceramic, a porous metal, and a porous hydroxyapatite.
In a variation, the shape is generally cylindrical. In another variation, the marker has a lower density core region and a higher density surface region. A water-impermeable coating layer may be provided to seal the marker against penetration by fluid, particularly where the voids within are channeling voids. In a particular embodiment the marker is of hydroxyapatite and in a further, more specific variation, the surface region of the marker has a higher density.
According to an embodiment, an intracorporeal marker for marking a site within living tissue of a host has a porous body of hydroxyapatite. The pores of the porous body are of such a size as to maximize the visibility of the body under ultrasonic imaging. In a variant, the body has a surface of higher density than a major fraction beneath the surface.
According to an embodiment, an intracorporeal marker marks a site within living tissue of a host. The marker includes a body of porous hydroxyapatite whose physical properties permit the body to be distinguished from human soft tissue under visualization using ultrasonic and radiation imaging modalities. The body can have various shapes, a preferred shape is a cylindrical shape. In a preferred embodiment, the body has gas-filled pores. In another preferred embodiment, the body has a core and a surface region, the core region having a lower density than the surface region.
Note that, as used in this specification, the term soft tissue is intended to characterize non-skeletal tissue which relatively transparent to X-rays such that tissue such as bone and some ligaments, cartilage, and fibrous tissue can be distinguished from it. Thus, a hydroxyapatite marker may be substantially visible under X-rays when placed in soft-tissue but might be hard to distinguish from non-soft-tissue.
According to another embodiment, an intracorporeal marker marks a site within living tissue of a host. The body includes at least one material that exhibits detectable difference in acoustical impedance relative to human soft tissue. The at least one material also exhibits detectable difference in radiation impedance relative to human soft tissue. The at least one material includes at least one of porous ceramic and a porous metal. Preferably, the body has a shape that is generally cylindrical. In a variation of the embodiment, the body has a core and a surface region, the core region having a lower density than the surface region. In another variation of the embodiment, the body has a surface and the surface has a water-impermeable coating layer. The at least one material preferably includes hydroxyapatite and preferably the material is solely hydroxyapatite.
According to another embodiment, an intracorporeal marker marks a site within living tissue of a host. The marker has a porous body of hydroxyapatite, the body having pores filled with gas. The sizes of the pores and the gas are such that the body can be visualized under ultrasound. In a variation, the body has a core and a surface region, the core region having a lower density than the surface region.
According to another embodiment, a method of in vivo identification of a position in soft tissue includes inserting a marker containing hydroxyapatite at a position in soft tissue of a living host; passing ultrasonic energy through the soft tissue to form an ultrasound image of the marker; and passing radiant energy through the soft tissue to form an X-ray image of the marker. Preferably, the hydroxyapatite defines a porous structure and more preferably, the body consists substantially of hydroxyapatite.
According to another method of in vivo identification of a position in soft tissue, a marker containing hydroxyapatite is inserted at a position in soft tissue of a living host. Ultrasonic energy is then passed through the living host to form an ultrasound image of the marker. The image is then used to locate a site for a medical treatment. Preferably, the hydroxyapatite is porous. The marker may consist substantially of hydroxyapatite.
According to another embodiment, a method of in vivo identification of a position in soft tissue, includes: inserting a marker containing hydroxyapatite at a position in soft tissue of a living host; passing radiant energy through the living host to form an X-ray image of the marker using the image to locate a site for a medical treatment. Preferably, the hydroxyapatite is porous. The marker may consist substantially of hydroxyapatite.
According to another embodiment, a method of in vivo identification of a position in soft tissue, includes: inserting a marker containing a porous ceramic at a position in soft tissue of a living host; passing ultrasonic energy through the living host to form an ultrasound image of the marker; passing radiant energy through the living host to form an X-ray image of the marker; using the image to locate a site for a medical treatment. Preferably, the porous ceramic includes hydroxyapatite and more preferably, the porous ceramic is substantially made of hydroxyapatite.
According to another embodiment, a method of in vivo identification of a position in soft tissue, includes: inserting a marker containing a porous ceramic at a position in soft tissue of a living host; passing ultrasonic energy through the living host to form an ultrasound image of the marker; passing energy through the living host to form an image of the marker based on a non-ultrasound imaging modality; using the image to locate a site for a medical treatment. Preferably, the porous ceramic includes hydroxyapatite and more preferably, the porous ceramic is substantially made of hydroxyapatite.
The accompanying drawings, which are incorporated herein and constitute part of this specification, illustrate exemplary embodiments of the invention, and, together with the general description given above and the detailed description given below, serve to explain the features of the invention.
Ceramics with voids in them, such as ceramic foams, are often used as filtering materials. Some are used for filtering molten metal, for example. Such materials may be manufactured in a variety of different ways. Ceramic foam filters are generally made by impregnating a polymeric foam with an aqueous slurry of ceramic material containing a binder. The impregnated foam is dried to remove water, and the dried impregnated foam is fired to eliminate the polymer material. This leaves the ceramic foam. This process is often used to create a channelized product but recipe variations, such as a lower quantity of foaming agent, can produce non-channelized product.
Foamed glass methods of manufacture and articles of manufacture are disclosed in U.S. Pat. No. 5,972,817, “Foamed Glass Article for Preparing Surfaces, Use Therefor, and Method of Making Same” to Haines et al.; U.S. Pat. No. 5,821,184, “Foamed Glass Article for Preparing Surfaces, Use Therefore and Method of Making Same” to Haines et al.; U.S. Pat. No. 5,928,773, “Foamed Glass Articles and Methods of Making Same and Methods of Controlling the PH of Same Within Specific Limits” to James C. Andersen; and published US Pat. Appl. No. 20040016195 for “Foamed glass article for use as thermal energy control media;” each of which is hereby incorporated by reference and attached hereto as if fully set forth herein.
The voids may channel; i.e., they may generally intersect or communicate with each other and the external surface. Alternatively, they may be of a so-called closed cell type where the voids do not communicate with each other or the external surface. In void channeling materials or materials which are naturally rough or porous, it is preferred for the matrix to be hydrophobic or that the surface of the marker be sealed by an impermeable, preferably hydrophobic, coating. This helps to resist filling of the voids or surface pits with aqueous fluid.
Although referred to as porous, the materials above may include one or more discrete voids formed non-randomly. For example, the voids may be formed by binding filaments of the marker material together, for example ultrasonic welding of thin wires to form voids in a metal marker or component of a marker. Voids may be also be formed by other processes such as machining, chemical etching, laser etching, etc. In general, where the embodiments are described as being porous, such alternative types of voids, including a single void chamber, are also contemplated. The voids may be formed by entrapping a biocompatible gas within the void or voids.
The markers may be incubated in carbon dioxide atmosphere to fill the voids with the gas. As discussed above, various methods may be used to create the hydroxyapatite bodies. These methods include but not limited to: molding the hydroxyapatite particles to a desired geometry and then sintering the green mass. The preferred porosity levels in porous Hydroxyapatite could range from 30% to 80%, and more preferably, from 60 to 80%.
Preferably porous portions are have a sufficient void fraction and a size chosen to ensure the marker is distinct under ultrasonic imaging. Porous ceramic material can be produced by sintering particles with a sufficient void fraction to make the resulting article distinct under ultrasound. As indicated above, ceramics containing mixtures of materials may be employed to enhance radio-opacity. For example, ceramics can contain metallic inclusions. Ceramic particles (or metal-ceramic particle mixtures) having a packing density of a desired fraction, for example 70%, may be sintered to create a mass. The result may have no or limited connections between the void spaces so that the result needs no impermeable jacket to avoid the voids filling with fluids. Alternatively, a coating may be provided to prevent ingress of moisture. The coating need not be mechanically continuous over the article if it is sufficient to retard ingress of moisture. For example, the coating material may be hydrophobic. In a variation, techniques used for making refractory foams may be employed to create a marker.
In embodiments where a biocompatible porous metal is used the metal porosity may be obtained by compacting a metal powder to a desired shape in presence of a polymeric and non-polymeric binder and then sintering the metal powder particles to form a homogenous metal mass with predetermined porosity/density. Many metals and alloys suitable for long term implant could be used and these include but not limited to: Nitinol, gold, silver, stainless steel, cobalt-chromium alloy, titanium, tantalum, and tungsten or combination thereof.
The shape of the marker can depend on the clinical application. In general cylindrical, spherical, disk like shapes are preferred. Irregular shapes may also be used.
According to a feature of the above embodiments, a marker of the any of the above described structures and compositions may be used according to the following method which may include steps 1 and 2, steps 1 through 3, or steps 1 through 4, according to different embodiments.
Step 1. Insert a marker at a location. The location can be marked at a time and location of biopsy or otherwise positioned in a tissue mass.
Step 2. Identify a location of the marker using a first imaging modality. The modality may be X-ray-based imaging or ultrasound-based imaging. This step may include passing a corresponding form of energy through a soft tissue mass of a living host.
Step 3. Identify a location of the marker using a second imaging modality that is different from the first imaging modality in step 2. The second imaging modality may be X-ray-based imaging or ultrasound-based imaging. This step may also include passing a corresponding form of energy through a soft tissue mass of a living host.
Step 4. Surgically remove the marker.
Note that while the principal embodiments described above had a generally symmetrical configuration, it is also possible to form asymmetrical embodiments. For example, bodies having different materials that can be imaged using different modalities can be located adjacent each other on respective sides of the body. Also, for example, cylindrical embodiments with a low density portion and high density portion, each on a respective side of the axis in a first embodiment, or each on a respective end of (displaced along the axis) could be provided. Thus, the manner in which material is distributed is not necessarily confined to the particular examples shown. Such embodiments could be imaged using multiple imaging modalities.
While the present invention has been disclosed with reference to certain embodiments, numerous modifications, alterations, and changes to the described embodiments are possible without departing from the sphere and scope of the present invention, as defined in the appended claims. Accordingly, it is intended that the present invention not be limited to the described embodiments, but that it has the full scope defined by the language of the following claims, and equivalents thereof.
This application is a U.S. nation phase of International Application No. PCT/US2007/087211, filed Dec. 12, 2007, which claims priority to U.S. Provisional Patent Application No. 60/869,636, filed Dec. 12, 2006, which are incorporated herein by reference in their entirety.
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/US2007/087211 | 12/12/2007 | WO | 00 | 6/11/2009 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2008/073965 | 6/19/2008 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
2192270 | McGowan | Mar 1940 | A |
2481408 | Fuller et al. | Sep 1949 | A |
2832888 | Houston | Apr 1958 | A |
2899362 | Sieger, Jr. et al. | Aug 1959 | A |
2907327 | White | Oct 1959 | A |
3341417 | Sinaiko | Sep 1967 | A |
3402712 | Eisenhand | Sep 1968 | A |
3516412 | Ackerman | Jun 1970 | A |
3593343 | Viggers | Jul 1971 | A |
3757781 | Smart | Sep 1973 | A |
3818894 | Wichterle et al. | Jun 1974 | A |
3823212 | Chvapil | Jul 1974 | A |
3921632 | Bardani | Nov 1975 | A |
4005699 | Bucalo | Feb 1977 | A |
4007732 | Kvavle et al. | Feb 1977 | A |
4041931 | Elliott et al. | Aug 1977 | A |
4103690 | Harris | Aug 1978 | A |
4105030 | Kercso | Aug 1978 | A |
4172449 | LeRoy et al. | Oct 1979 | A |
4197846 | Bucalo | Apr 1980 | A |
4217889 | Radovan et al. | Aug 1980 | A |
4276885 | Tickner et al. | Jul 1981 | A |
4294241 | Miyata | Oct 1981 | A |
4298998 | Naficy | Nov 1981 | A |
4331654 | Morris | May 1982 | A |
4390018 | Zukowski | Jun 1983 | A |
4400170 | McNaughton et al. | Aug 1983 | A |
4401124 | Guess et al. | Aug 1983 | A |
4405314 | Cope | Sep 1983 | A |
4428082 | Naficy | Jan 1984 | A |
4438253 | Casey et al. | Mar 1984 | A |
4442843 | Rasor et al. | Apr 1984 | A |
4470160 | Cavon | Sep 1984 | A |
4487209 | Mehl | Dec 1984 | A |
4545367 | Tucci | Oct 1985 | A |
4549560 | Andis | Oct 1985 | A |
4582061 | Fry | Apr 1986 | A |
4582640 | Smestad et al. | Apr 1986 | A |
4588395 | Lemelson | May 1986 | A |
4597753 | Turley | Jul 1986 | A |
4647480 | Ahmed | Mar 1987 | A |
4655226 | Lee | Apr 1987 | A |
4661103 | Harman | Apr 1987 | A |
4682606 | DeCaprio | Jul 1987 | A |
4693237 | Hoffman et al. | Sep 1987 | A |
4740208 | Cavon | Apr 1988 | A |
4762128 | Rosenbluth | Aug 1988 | A |
4813062 | Gilpatrick | Mar 1989 | A |
4820267 | Harman | Apr 1989 | A |
4832680 | Haber et al. | May 1989 | A |
4832686 | Anderson | May 1989 | A |
4847049 | Yamamoto | Jul 1989 | A |
4863470 | Carter | Sep 1989 | A |
4870966 | Dellon et al. | Oct 1989 | A |
4874376 | Hawkins, Jr. | Oct 1989 | A |
4889707 | Day et al. | Dec 1989 | A |
4909250 | Smith | Mar 1990 | A |
4938763 | Dunn et al. | Jul 1990 | A |
4950665 | Floyd | Aug 1990 | A |
4963150 | Brauman | Oct 1990 | A |
4970298 | Silver et al. | Nov 1990 | A |
4989608 | Ratner | Feb 1991 | A |
4994013 | Suthanthiran et al. | Feb 1991 | A |
4994028 | Leonard et al. | Feb 1991 | A |
5012818 | Joishy | May 1991 | A |
5059197 | Urie et al. | Oct 1991 | A |
5081997 | Bosley, Jr. et al. | Jan 1992 | A |
5120802 | Mares et al. | Jun 1992 | A |
5125413 | Baran | Jun 1992 | A |
5137928 | Erbel et al. | Aug 1992 | A |
5141748 | Rizzo | Aug 1992 | A |
5147307 | Gluck | Sep 1992 | A |
5147631 | Glajch et al. | Sep 1992 | A |
5162430 | Rhee et al. | Nov 1992 | A |
5163896 | Suthanthiran et al. | Nov 1992 | A |
5195540 | Shiber | Mar 1993 | A |
5197482 | Rank et al. | Mar 1993 | A |
5197846 | Uno et al. | Mar 1993 | A |
5199441 | Hogle | Apr 1993 | A |
5219339 | Saito | Jun 1993 | A |
5221269 | Miller et al. | Jun 1993 | A |
5231615 | Endoh | Jul 1993 | A |
5236410 | Granov et al. | Aug 1993 | A |
5242759 | Hall | Sep 1993 | A |
5250026 | Ehrlich et al. | Oct 1993 | A |
5271961 | Mathiowitz et al. | Dec 1993 | A |
5273532 | Niezink et al. | Dec 1993 | A |
5280788 | Janes et al. | Jan 1994 | A |
5281197 | Arias et al. | Jan 1994 | A |
5281408 | Unger | Jan 1994 | A |
5282781 | Liprie | Feb 1994 | A |
5284479 | de Jong | Feb 1994 | A |
5289831 | Bosley | Mar 1994 | A |
5320100 | Herweck et al. | Jun 1994 | A |
5320613 | Houge et al. | Jun 1994 | A |
5328955 | Rhee et al. | Jul 1994 | A |
5334381 | Unger | Aug 1994 | A |
5344640 | Deutsch et al. | Sep 1994 | A |
5353804 | Kornberg et al. | Oct 1994 | A |
5354623 | Hall | Oct 1994 | A |
5358514 | Schulman et al. | Oct 1994 | A |
5366756 | Chesterfield et al. | Nov 1994 | A |
5368030 | Zinreich et al. | Nov 1994 | A |
5388588 | Nabai et al. | Feb 1995 | A |
5394875 | Lewis et al. | Mar 1995 | A |
5395319 | Hirsch et al. | Mar 1995 | A |
5409004 | Sloan | Apr 1995 | A |
5417708 | Hall et al. | May 1995 | A |
5422730 | Barlow et al. | Jun 1995 | A |
5425366 | Reinhardt et al. | Jun 1995 | A |
5431639 | Shaw | Jul 1995 | A |
5433204 | Olson | Jul 1995 | A |
5449560 | Antheunis et al. | Sep 1995 | A |
5451406 | Lawin et al. | Sep 1995 | A |
5460182 | Goodman et al. | Oct 1995 | A |
5469847 | Zinreich et al. | Nov 1995 | A |
5475052 | Rhee et al. | Dec 1995 | A |
5490521 | Davis et al. | Feb 1996 | A |
5494030 | Swartz et al. | Feb 1996 | A |
5499989 | LaBash | Mar 1996 | A |
5507807 | Shippert | Apr 1996 | A |
5508021 | Grinstaff et al. | Apr 1996 | A |
5514085 | Yoon | May 1996 | A |
5522896 | Prescott | Jun 1996 | A |
5538726 | Order | Jul 1996 | A |
5542915 | Edwards et al. | Aug 1996 | A |
5549560 | Van de Wijdeven | Aug 1996 | A |
RE35391 | Brauman | Dec 1996 | E |
5580568 | Greff et al. | Dec 1996 | A |
5585112 | Unger et al. | Dec 1996 | A |
5611352 | Kobren et al. | Mar 1997 | A |
5626611 | Liu et al. | May 1997 | A |
5628781 | Williams et al. | May 1997 | A |
5629008 | Lee | May 1997 | A |
5636255 | Ellis | Jun 1997 | A |
5643246 | Leeb et al. | Jul 1997 | A |
5646146 | Faarup et al. | Jul 1997 | A |
5665092 | Mangiardi et al. | Sep 1997 | A |
5667767 | Greff et al. | Sep 1997 | A |
5669882 | Pyles | Sep 1997 | A |
5673841 | Schulze et al. | Oct 1997 | A |
5676146 | Scarborough | Oct 1997 | A |
5676925 | Klaveness et al. | Oct 1997 | A |
5688490 | Tournier et al. | Nov 1997 | A |
5690120 | Jacobsen et al. | Nov 1997 | A |
5695480 | Evans et al. | Dec 1997 | A |
5702128 | Maxim et al. | Dec 1997 | A |
5702716 | Dunn et al. | Dec 1997 | A |
5716981 | Hunter et al. | Feb 1998 | A |
5747060 | Sackler et al. | May 1998 | A |
5762903 | Park et al. | Jun 1998 | A |
5769086 | Ritchart et al. | Jun 1998 | A |
5776496 | Violante et al. | Jul 1998 | A |
5779647 | Chau et al. | Jul 1998 | A |
5782764 | Werne | Jul 1998 | A |
5782775 | Milliman et al. | Jul 1998 | A |
5795308 | Russin | Aug 1998 | A |
5799099 | Wang et al. | Aug 1998 | A |
5800362 | Kobren et al. | Sep 1998 | A |
5800389 | Burney et al. | Sep 1998 | A |
5800445 | Ratcliff et al. | Sep 1998 | A |
5800541 | Rhee et al. | Sep 1998 | A |
5817022 | Vesely | Oct 1998 | A |
5820918 | Ronan et al. | Oct 1998 | A |
5821184 | Haines et al. | Oct 1998 | A |
5823198 | Jones et al. | Oct 1998 | A |
5824042 | Lombardi et al. | Oct 1998 | A |
5824081 | Knapp et al. | Oct 1998 | A |
5826776 | Schulze et al. | Oct 1998 | A |
5830178 | Jones et al. | Nov 1998 | A |
5842477 | Naughton et al. | Dec 1998 | A |
5842999 | Pruitt et al. | Dec 1998 | A |
5845646 | Lemelson | Dec 1998 | A |
5846220 | Elsberry | Dec 1998 | A |
5851508 | Greff et al. | Dec 1998 | A |
5853366 | Dowlatshahi | Dec 1998 | A |
5865806 | Howell | Feb 1999 | A |
5869080 | McGregor et al. | Feb 1999 | A |
5871501 | Leschinsky et al. | Feb 1999 | A |
5876340 | Tu et al. | Mar 1999 | A |
5879357 | Heaton et al. | Mar 1999 | A |
5891558 | Bell et al. | Apr 1999 | A |
5897507 | Kortenbach et al. | Apr 1999 | A |
5902310 | Foerster et al. | May 1999 | A |
5911705 | Howell | Jun 1999 | A |
5916164 | Fitzpatrick et al. | Jun 1999 | A |
5921933 | Sarkis et al. | Jul 1999 | A |
5922024 | Janzen et al. | Jul 1999 | A |
5928626 | Klaveness et al. | Jul 1999 | A |
5928773 | Andersen | Jul 1999 | A |
5941439 | Kammerer et al. | Aug 1999 | A |
5941890 | Voegele et al. | Aug 1999 | A |
5942209 | Leavitt et al. | Aug 1999 | A |
5948425 | Janzen et al. | Sep 1999 | A |
5954670 | Baker | Sep 1999 | A |
5972817 | Haines et al. | Oct 1999 | A |
5980564 | Stinson | Nov 1999 | A |
5989265 | Bouquet De La Joliniere et al. | Nov 1999 | A |
6015541 | Greff et al. | Jan 2000 | A |
6030333 | Sioshansi et al. | Feb 2000 | A |
6053925 | Barnhart | Apr 2000 | A |
6056700 | Burney et al. | May 2000 | A |
6066122 | Fisher | May 2000 | A |
6066325 | Wallace et al. | May 2000 | A |
6071301 | Cragg et al. | Jun 2000 | A |
6071310 | Picha et al. | Jun 2000 | A |
6071496 | Stein et al. | Jun 2000 | A |
6090996 | Li | Jul 2000 | A |
6096065 | Crowley | Aug 2000 | A |
6096070 | Ragheb et al. | Aug 2000 | A |
6106473 | Violante et al. | Aug 2000 | A |
6117108 | Woehr et al. | Sep 2000 | A |
6120536 | Ding et al. | Sep 2000 | A |
6142955 | Farascioni et al. | Nov 2000 | A |
6159240 | Sparer et al. | Dec 2000 | A |
6159445 | Klaveness et al. | Dec 2000 | A |
6161034 | Burbank et al. | Dec 2000 | A |
6162192 | Cragg et al. | Dec 2000 | A |
6173715 | Sinanan et al. | Jan 2001 | B1 |
6174330 | Stinson | Jan 2001 | B1 |
6177062 | Stein et al. | Jan 2001 | B1 |
6181960 | Jensen et al. | Jan 2001 | B1 |
6183497 | Sing et al. | Feb 2001 | B1 |
6190350 | Davis et al. | Feb 2001 | B1 |
6190353 | Makower et al. | Feb 2001 | B1 |
6200258 | Slater et al. | Mar 2001 | B1 |
6203524 | Burney et al. | Mar 2001 | B1 |
6203568 | Lombardi et al. | Mar 2001 | B1 |
6213957 | Milliman et al. | Apr 2001 | B1 |
6214045 | Corbitt, Jr. et al. | Apr 2001 | B1 |
6214315 | Greff et al. | Apr 2001 | B1 |
6220248 | Voegele et al. | Apr 2001 | B1 |
6224630 | Bao et al. | May 2001 | B1 |
6228049 | Schroeder et al. | May 2001 | B1 |
6228055 | Foerster et al. | May 2001 | B1 |
6231615 | Preissman | May 2001 | B1 |
6234177 | Barsch | May 2001 | B1 |
6241687 | Voegele et al. | Jun 2001 | B1 |
6241734 | Scribner et al. | Jun 2001 | B1 |
6251418 | Ahern et al. | Jun 2001 | B1 |
6261243 | Burney et al. | Jul 2001 | B1 |
6261302 | Voegele et al. | Jul 2001 | B1 |
6264917 | Klaveness et al. | Jul 2001 | B1 |
6270464 | Fulton, III et al. | Aug 2001 | B1 |
6270472 | Antaki et al. | Aug 2001 | B1 |
6287278 | Woehr et al. | Sep 2001 | B1 |
6287332 | Bolz et al. | Sep 2001 | B1 |
6289229 | Crowley | Sep 2001 | B1 |
6306154 | Hudson et al. | Oct 2001 | B1 |
6312429 | Burbank et al. | Nov 2001 | B1 |
6316522 | Loomis et al. | Nov 2001 | B1 |
6335029 | Kamath et al. | Jan 2002 | B1 |
6336904 | Nikolchev | Jan 2002 | B1 |
6340367 | Stinson et al. | Jan 2002 | B1 |
6343227 | Crowley | Jan 2002 | B1 |
6347240 | Foley et al. | Feb 2002 | B1 |
6347241 | Burbank et al. | Feb 2002 | B2 |
6350244 | Fisher | Feb 2002 | B1 |
6350274 | Li | Feb 2002 | B1 |
6354989 | Nudeshima | Mar 2002 | B1 |
6356112 | Tran et al. | Mar 2002 | B1 |
6356782 | Sirimanne et al. | Mar 2002 | B1 |
6358217 | Bourassa | Mar 2002 | B1 |
6363940 | Krag | Apr 2002 | B1 |
6371904 | Sirimanne et al. | Apr 2002 | B1 |
6394965 | Klein | May 2002 | B1 |
6403758 | Loomis | Jun 2002 | B1 |
6405733 | Fogarty et al. | Jun 2002 | B1 |
6409742 | Fulton, III et al. | Jun 2002 | B1 |
6424857 | Henrichs et al. | Jul 2002 | B1 |
6425903 | Voegele | Jul 2002 | B1 |
6427081 | Burbank et al. | Jul 2002 | B1 |
6436030 | Rehil | Aug 2002 | B2 |
6450937 | Mercereau et al. | Sep 2002 | B1 |
6450938 | Miller | Sep 2002 | B1 |
6471700 | Burbank et al. | Oct 2002 | B1 |
6478790 | Bardani | Nov 2002 | B2 |
6506156 | Jones et al. | Jan 2003 | B1 |
6511468 | Cragg et al. | Jan 2003 | B1 |
6537193 | Lennox | Mar 2003 | B1 |
6540981 | Klaveness et al. | Apr 2003 | B2 |
6544185 | Montegrande | Apr 2003 | B2 |
6551253 | Worm et al. | Apr 2003 | B2 |
6554760 | Lamoureux et al. | Apr 2003 | B2 |
6562317 | Greff et al. | May 2003 | B2 |
6564806 | Fogarty et al. | May 2003 | B1 |
6565551 | Jones et al. | May 2003 | B1 |
6567689 | Burbank et al. | May 2003 | B2 |
6575888 | Zamora et al. | Jun 2003 | B2 |
6575991 | Chesbrough et al. | Jun 2003 | B1 |
6585773 | Xie | Jul 2003 | B1 |
6605047 | Zarins et al. | Aug 2003 | B2 |
6610026 | Cragg et al. | Aug 2003 | B2 |
6613002 | Clark et al. | Sep 2003 | B1 |
6616630 | Woehr et al. | Sep 2003 | B1 |
6626850 | Chau et al. | Sep 2003 | B1 |
6628982 | Thomas et al. | Sep 2003 | B1 |
6636758 | Sanchez et al. | Oct 2003 | B2 |
6638234 | Burbank et al. | Oct 2003 | B2 |
6638308 | Corbitt, Jr. et al. | Oct 2003 | B2 |
6652442 | Gatto | Nov 2003 | B2 |
6656192 | Espositio et al. | Dec 2003 | B2 |
6662041 | Burbank et al. | Dec 2003 | B2 |
6699205 | Fulton, III et al. | Mar 2004 | B2 |
6712774 | Voegele et al. | Mar 2004 | B2 |
6712836 | Berg et al. | Mar 2004 | B1 |
6716444 | Castro et al. | Apr 2004 | B1 |
6725083 | Burbank et al. | Apr 2004 | B1 |
6730042 | Fulton et al. | May 2004 | B2 |
6730044 | Stephens et al. | May 2004 | B2 |
6746661 | Kaplan | Jun 2004 | B2 |
6746773 | Llanos et al. | Jun 2004 | B2 |
6752154 | Fogarty et al. | Jun 2004 | B2 |
6766186 | Hoyns et al. | Jul 2004 | B1 |
6774278 | Ragheb et al. | Aug 2004 | B1 |
6780179 | Lee et al. | Aug 2004 | B2 |
6824507 | Miller | Nov 2004 | B2 |
6824527 | Gollobin | Nov 2004 | B2 |
6846320 | Ashby et al. | Jan 2005 | B2 |
6862470 | Burbank et al. | Mar 2005 | B2 |
6863685 | Davila et al. | Mar 2005 | B2 |
6881226 | Corbitt, Jr. et al. | Apr 2005 | B2 |
6899731 | Li et al. | May 2005 | B2 |
6918927 | Bates et al. | Jul 2005 | B2 |
6936014 | Vetter et al. | Aug 2005 | B2 |
6939318 | Stenzel | Sep 2005 | B2 |
6945973 | Bray | Sep 2005 | B2 |
6951564 | Espositio et al. | Oct 2005 | B2 |
6992233 | Drake et al. | Jan 2006 | B2 |
6993375 | Burbank et al. | Jan 2006 | B2 |
6994712 | Fisher et al. | Feb 2006 | B1 |
6996433 | Burbank et al. | Feb 2006 | B2 |
7001341 | Gellman et al. | Feb 2006 | B2 |
7008382 | Adams et al. | Mar 2006 | B2 |
7014610 | Koulik | Mar 2006 | B2 |
7025765 | Balbierz et al. | Apr 2006 | B2 |
7044957 | Foerster et al. | May 2006 | B2 |
7047063 | Burbank et al. | May 2006 | B2 |
7083576 | Zarins et al. | Aug 2006 | B2 |
7125397 | Woehr et al. | Oct 2006 | B2 |
7160258 | Imran et al. | Jan 2007 | B2 |
7172549 | Slater et al. | Feb 2007 | B2 |
7214211 | Woehr et al. | May 2007 | B2 |
7229417 | Foerster et al. | Jun 2007 | B2 |
7236816 | Kumar et al. | Jun 2007 | B2 |
7264613 | Woehr et al. | Sep 2007 | B2 |
7294118 | Saulenas et al. | Nov 2007 | B2 |
7297725 | Winterton et al. | Nov 2007 | B2 |
7329402 | Unger et al. | Feb 2008 | B2 |
7329414 | Fisher et al. | Feb 2008 | B2 |
7416533 | Gellman et al. | Aug 2008 | B2 |
7424320 | Chesbrough et al. | Sep 2008 | B2 |
7449000 | Adams et al. | Nov 2008 | B2 |
7527610 | Erickson | May 2009 | B2 |
7534452 | Chernomorsky et al. | May 2009 | B2 |
7569065 | Chesbrough et al. | Aug 2009 | B2 |
7577473 | Davis et al. | Aug 2009 | B2 |
7637948 | Corbitt, Jr. | Dec 2009 | B2 |
7651505 | Lubock et al. | Jan 2010 | B2 |
7877133 | Burbank et al. | Jan 2011 | B2 |
20010006616 | Leavitt et al. | Jul 2001 | A1 |
20020004060 | Heublein et al. | Jan 2002 | A1 |
20020016625 | Falotico et al. | Feb 2002 | A1 |
20020022883 | Burg | Feb 2002 | A1 |
20020026201 | Foerster et al. | Feb 2002 | A1 |
20020035324 | Sirimanne et al. | Mar 2002 | A1 |
20020045842 | Van Bladel et al. | Apr 2002 | A1 |
20020052572 | Franco et al. | May 2002 | A1 |
20020055731 | Atala et al. | May 2002 | A1 |
20020058868 | Hoshino et al. | May 2002 | A1 |
20020058882 | Fulton, III et al. | May 2002 | A1 |
20020077687 | Ahn | Jun 2002 | A1 |
20020082517 | Klein | Jun 2002 | A1 |
20020082519 | Miller et al. | Jun 2002 | A1 |
20020082682 | Barclay et al. | Jun 2002 | A1 |
20020082683 | Stinson et al. | Jun 2002 | A1 |
20020095204 | Thompson et al. | Jul 2002 | A1 |
20020095205 | Edwin et al. | Jul 2002 | A1 |
20020107437 | Sirimanne et al. | Aug 2002 | A1 |
20020133148 | Daniel et al. | Sep 2002 | A1 |
20020143359 | Fulton, III et al. | Oct 2002 | A1 |
20020165608 | Llanos et al. | Nov 2002 | A1 |
20020188196 | Burbank et al. | Dec 2002 | A1 |
20020193815 | Foerster et al. | Dec 2002 | A1 |
20020193867 | Gladdish, Jr. et al. | Dec 2002 | A1 |
20030032969 | Gannoe et al. | Feb 2003 | A1 |
20030036803 | McGhan | Feb 2003 | A1 |
20030051735 | Pavcnik et al. | Mar 2003 | A1 |
20030116806 | Kato | Jun 2003 | A1 |
20030165478 | Sokoll | Sep 2003 | A1 |
20030191355 | Ferguson | Oct 2003 | A1 |
20030199887 | Ferrera et al. | Oct 2003 | A1 |
20030225420 | Wardle | Dec 2003 | A1 |
20030233101 | Lubock et al. | Dec 2003 | A1 |
20030236573 | Evans et al. | Dec 2003 | A1 |
20040001841 | Nagavarapu et al. | Jan 2004 | A1 |
20040002650 | Mandrusov et al. | Jan 2004 | A1 |
20040016195 | Archuleta | Jan 2004 | A1 |
20040024304 | Foerster et al. | Feb 2004 | A1 |
20040059341 | Gellman et al. | Mar 2004 | A1 |
20040073107 | Sioshansi et al. | Apr 2004 | A1 |
20040073284 | Bates et al. | Apr 2004 | A1 |
20040097981 | Selis | May 2004 | A1 |
20040101479 | Burbank et al. | May 2004 | A1 |
20040101548 | Pendharkar | May 2004 | A1 |
20040106891 | Langan et al. | Jun 2004 | A1 |
20040116802 | Jessop et al. | Jun 2004 | A1 |
20040124105 | Seiler et al. | Jul 2004 | A1 |
20040127765 | Seiler et al. | Jul 2004 | A1 |
20040133124 | Bates et al. | Jul 2004 | A1 |
20040162574 | Viola | Aug 2004 | A1 |
20040167619 | Case et al. | Aug 2004 | A1 |
20040204660 | Fulton et al. | Oct 2004 | A1 |
20040210208 | Paul et al. | Oct 2004 | A1 |
20040213756 | Michal et al. | Oct 2004 | A1 |
20040236212 | Jones et al. | Nov 2004 | A1 |
20040236213 | Jones et al. | Nov 2004 | A1 |
20050020916 | MacFarlane et al. | Jan 2005 | A1 |
20050033157 | Klein et al. | Feb 2005 | A1 |
20050033195 | Fulton et al. | Feb 2005 | A1 |
20050036946 | Pathak et al. | Feb 2005 | A1 |
20050045192 | Fulton et al. | Mar 2005 | A1 |
20050059887 | Mostafavi et al. | Mar 2005 | A1 |
20050059888 | Sirimanne et al. | Mar 2005 | A1 |
20050065354 | Roberts | Mar 2005 | A1 |
20050065453 | Shabaz et al. | Mar 2005 | A1 |
20050080337 | Sirimanne et al. | Apr 2005 | A1 |
20050080339 | Sirimanne et al. | Apr 2005 | A1 |
20050085724 | Sirimanne et al. | Apr 2005 | A1 |
20050100580 | Osborne et al. | May 2005 | A1 |
20050113659 | Pothier et al. | May 2005 | A1 |
20050119562 | Jones et al. | Jun 2005 | A1 |
20050143650 | Winkel | Jun 2005 | A1 |
20050165305 | Foerster et al. | Jul 2005 | A1 |
20050175657 | Hunter et al. | Aug 2005 | A1 |
20050181007 | Hunter et al. | Aug 2005 | A1 |
20050208122 | Allen et al. | Sep 2005 | A1 |
20050234336 | Beckman et al. | Oct 2005 | A1 |
20050268922 | Conrad et al. | Dec 2005 | A1 |
20050273002 | Goosen et al. | Dec 2005 | A1 |
20050277871 | Selis | Dec 2005 | A1 |
20060004440 | Stinson | Jan 2006 | A1 |
20060009800 | Christianson et al. | Jan 2006 | A1 |
20060025677 | Verard et al. | Feb 2006 | A1 |
20060025795 | Chesbrough et al. | Feb 2006 | A1 |
20060036158 | Field et al. | Feb 2006 | A1 |
20060036159 | Sirimanne et al. | Feb 2006 | A1 |
20060036165 | Burbank et al. | Feb 2006 | A1 |
20060074443 | Foerster et al. | Apr 2006 | A1 |
20060079770 | Sirimanne et al. | Apr 2006 | A1 |
20060079805 | Miller et al. | Apr 2006 | A1 |
20060079829 | Fulton et al. | Apr 2006 | A1 |
20060079888 | Mulier et al. | Apr 2006 | A1 |
20060116573 | Field et al. | Jun 2006 | A1 |
20060122503 | Burbank et al. | Jun 2006 | A1 |
20060155190 | Burbank et al. | Jul 2006 | A1 |
20060173280 | Goosen et al. | Aug 2006 | A1 |
20060173296 | Miller et al. | Aug 2006 | A1 |
20060177379 | Asgari | Aug 2006 | A1 |
20060217635 | McCombs et al. | Sep 2006 | A1 |
20060235298 | Kotmel et al. | Oct 2006 | A1 |
20060241385 | Dietz | Oct 2006 | A1 |
20060241411 | Field et al. | Oct 2006 | A1 |
20060292690 | Liu et al. | Dec 2006 | A1 |
20070021642 | Lamoureux et al. | Jan 2007 | A1 |
20070038145 | Field | Feb 2007 | A1 |
20070057794 | Gisselberg et al. | Mar 2007 | A1 |
20070083132 | Sharrow | Apr 2007 | A1 |
20070087026 | Field | Apr 2007 | A1 |
20070106152 | Kantrowitz et al. | May 2007 | A1 |
20070135711 | Chernomorsky et al. | Jun 2007 | A1 |
20070142725 | Hardin et al. | Jun 2007 | A1 |
20070167736 | Dietz et al. | Jul 2007 | A1 |
20070167749 | Yarnall et al. | Jul 2007 | A1 |
20070239118 | Ono et al. | Oct 2007 | A1 |
20070287933 | Phan et al. | Dec 2007 | A1 |
20080033280 | Lubock et al. | Feb 2008 | A1 |
20080039819 | Jones et al. | Feb 2008 | A1 |
20080091120 | Fisher | Apr 2008 | A1 |
20080097199 | Mullen | Apr 2008 | A1 |
20080188768 | Zarins et al. | Aug 2008 | A1 |
20080249436 | Darr | Oct 2008 | A1 |
20080269638 | Cooke et al. | Oct 2008 | A1 |
20080294039 | Jones et al. | Nov 2008 | A1 |
20090000629 | Hornscheidt et al. | Jan 2009 | A1 |
20090024225 | Stubbs | Jan 2009 | A1 |
20090030309 | Jones et al. | Jan 2009 | A1 |
20090069713 | Adams et al. | Mar 2009 | A1 |
20090076484 | Fukaya | Mar 2009 | A1 |
20090093714 | Chesbrough et al. | Apr 2009 | A1 |
20090131825 | Burbank et al. | May 2009 | A1 |
20090171198 | Jones et al. | Jul 2009 | A1 |
20090216118 | Jones et al. | Aug 2009 | A1 |
20100010341 | Talpade et al. | Jan 2010 | A1 |
20100030149 | Carr, Jr. | Feb 2010 | A1 |
20110184280 | Jones et al. | Jul 2011 | A1 |
20120078092 | Jones et al. | Mar 2012 | A1 |
20120116215 | Jones et al. | May 2012 | A1 |
Number | Date | Country |
---|---|---|
1029528 | May 1958 | DE |
0146699 | Jul 1985 | EP |
0255123 | Feb 1988 | EP |
0292936 | Nov 1988 | EP |
0458745 | Nov 1991 | EP |
0475077 | Mar 1992 | EP |
0552924 | Jul 1993 | EP |
0769281 | Apr 1997 | EP |
1114618 | Jul 2001 | EP |
1163888 | Dec 2001 | EP |
1281416 | Jun 2002 | EP |
1364628 | Nov 2003 | EP |
1493451 | Jan 2005 | EP |
1767167 | Mar 2007 | EP |
2646674 | Nov 1990 | FR |
708148 | Apr 1954 | GB |
2131757 | May 1990 | JP |
8906978 | Aug 1989 | WO |
9112823 | Sep 1991 | WO |
9314712 | Aug 1993 | WO |
9317671 | Sep 1993 | WO |
9317718 | Sep 1993 | WO |
9416647 | Aug 1994 | WO |
9507057 | Mar 1995 | WO |
9806346 | Feb 1998 | WO |
9908607 | Feb 1999 | WO |
9935966 | Jul 1999 | WO |
9951143 | Oct 1999 | WO |
0023124 | Apr 2000 | WO |
0024332 | May 2000 | WO |
0028554 | May 2000 | WO |
0054689 | Sep 2000 | WO |
0108578 | Feb 2001 | WO |
0170114 | Sep 2001 | WO |
0207786 | Jan 2002 | WO |
03000308 | Jan 2003 | WO |
2004045444 | Jun 2004 | WO |
2005013832 | Feb 2005 | WO |
2005089664 | Sep 2005 | WO |
2006012630 | Feb 2006 | WO |
2006056739 | Jun 2006 | WO |
2006097331 | Sep 2006 | WO |
2006105353 | Oct 2006 | WO |
2007069105 | Jun 2007 | WO |
2008077081 | Jun 2008 | WO |
Entry |
---|
Press release for Biopsys Ethicon Endo-Surgery (Europe) GmbH; The Mammotome Vacuum Biopsy System. From: http://www.medicine-news.com/articles/devices/mammotome.html. 3 pages. |
Johnson & Johnson: Breast Biopsy (minimally invasive): Surgical Technique: Steps in the MAMOTOME Surgical Procedure. From http://www.jnjgateway.com. 3 pages. |
Johnson & Johnson: New Minimally Invasive Breast Biopsy Device Receives Marketing Clearance in Canada; Aug. 6, 1999. From http://www.jnjgateway.com. 4 pages. |
Johnson & Johnson: MAMMOTOME HAND HELD Receives FDA Marketing Clearance for Minimally Invasive Breast Biopises; Sep. 1, 1999. From From http://www.jnjgateway.com. 5 pages. |
Johnson & Johnson: The Mammotome Breast Biopsy System. From: http://www.breastcareinfo.com/aboutm.htm. 6 pages. |
Cook Incorporated: Emoblization and Occlusion. From: www.cookgroup.com 6 pages. |
Liberman, Laura, et al. Percutaneous Removal of Malignant Mammographic Lesions at Stereotactic Vacuum-assisted Biopsy. From: The Departments of Radiology, Pathology, and Surgery. Memorial Sloan-Kettering Cancer Center. From the 1997 RSNA scientific assembly. vol. 206, No. 3. pp. 711-715. |
Armstong, J.S., et al., “Differential marking of Excision Planes in Screened Breast lesions By Organically Coloured Gelatins”, Journal of Clinical Pathology, Jul. 1990, No. 43 (7) pp. 604-607, XP000971447 abstract; tables 1,2. |
Fucci, V., et al., “Large Bowel Transit Times Using Radioopaque Markers in Normal Cats”, J. of Am. Animal Hospital Assn., Nov.-Dec. 1995 31 (6) 473-477. |
Schindlbeck, N.E., et al., “Measurement of Colon Transit Time”, J. of Gastroenterology, No. 28, pp. 399-404, 1990. |
Shiga, et al., Preparation of Poly(D, L-lactide) and Copoly(lactide-glycolide) Microspheres of Uniform Size, J. Pharm. Pharmacol. 1996 48:891-895. |
Eiselt, P. et al, “Development of Technologies Aiding Large-Tissue Engineering”, Biotechnol. Prog., vol. 14, No. 1, pp. 134-140, 1998. |
Fajardo, Laurie, et al., “Placement of Endovascular Embolization Microcoils to Localize the Site of Breast Lesions Removed at Stereotactic Core Biopsy”, Radiology, Jan. 1998, pp. 275-278, vol. 206—No. 1. |
H. J. Gent, M.D., et al., Stereotaxic Needle Localization and Cytological Diagnosis of Occult Breast Lesions, Annals of Surgery, Nov. 1986, pp. 580-584, vol. 204—No. 5. |
Meuris, Bart, “Calcification of Aortic Wall Tissue in Prosthetic Heart Valves: Initiation, Influencing Factors and Strategies Towards Prevention”, Thesis, 2007, pp. 21-36, Leuven University Press; Leuven, Belgium. |
Number | Date | Country | |
---|---|---|---|
20100030072 A1 | Feb 2010 | US |
Number | Date | Country | |
---|---|---|---|
60869636 | Dec 2006 | US |